KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Finished Goods: 2015-2018

  • Travere Therapeutics' Finished Goods fell 11.17% to $1.4 million in Q1 2018 from the same period last year, while for Mar 2018 it was $1.4 million, marking a year-over-year decrease of 11.17%. This contributed to the annual value of $1.9 million for FY2017, which is 28.59% up from last year.
  • Latest data reveals that Travere Therapeutics reported Finished Goods of $1.4 million as of Q1 2018, which was down 26.98% from $1.9 million recorded in Q4 2017.
  • Travere Therapeutics' Finished Goods' 5-year high stood at $2.5 million during Q2 2016, with a 5-year trough of $1.4 million in Q1 2018.
  • In the last 3 years, Travere Therapeutics' Finished Goods had a median value of $1.6 million in 2017 and averaged $1.8 million.
  • In the last 5 years, Travere Therapeutics' Finished Goods slumped by 33.69% in 2016 and then rose by 28.59% in 2017.
  • Travere Therapeutics' Finished Goods (Quarterly) stood at $2.2 million in 2015, then tumbled by 33.69% to $1.5 million in 2016, then grew by 28.59% to $1.9 million in 2017, then dropped by 11.17% to $1.4 million in 2018.
  • Its Finished Goods stands at $1.4 million for Q1 2018, versus $1.9 million for Q4 2017 and $1.6 million for Q1 2017.